UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

RWD130 European Health Data Space (EHDS) Requires Secure Processing Environments (SPEs) – Comparison of SPESiOR to Other SPE-Type Environments from Finnish, Nordic, European, and Global Settings

Value in health, 2024-06, Vol.27 (6), p.S383-S383

Soini, E

2024

Volltextzugriff (PDF)

Fluorescence-Based Cell Viability Screening Assays Using Water-Soluble Oxygen Probes

SLAS discovery, 2003-06, Vol.8 (3), p.264-272

2003

Volltextzugriff (PDF)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland

ClinicoEconomics and outcomes research, 2023-01, Vol.15, p.1-13

2023

Volltextzugriff (PDF)

PSY189 - TREATMENT GUIDELINE INCLUDING THE HEALTH ECONOMIC EVALUATIONS OF BIOLOGIC DRUGS USED FOR PSORIATIC ARTHRITIS: PICOSTEPS, SYSTEMATIC LITERATURE REVIEW, APPLICABILITY EVALUATION AND LEVEL OF EVIDENCE EVALUATION

Value in health, 2018-10, Vol.21, p.S468-S469

Soini, E.

2018

Volltextzugriff (PDF)

CP3 - PATIENTS-INTERVENTION-COMPARATORS-OUTCOMES-SETTINGS-TIME-EFFECTS-SENSITIVITY (PICOSTEPS): REPRESENTING EVIDENCE-BASED HEALTH ECONOMIC EVALUATIONS (EBHEE) IN THE ORDER OF IMPORTANCE

Value in health, 2018-10, Vol.21, p.S5-S5

Soini, E.

2018

Volltextzugriff (PDF)

Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Value in health, 2014-11, Vol.17 (7), p.A399-A399

2014

Volltextzugriff (PDF)

EE296 Should Hospitals Do Contract Research? Costs, Net Monetary Benefit, and Return on Public Sector Investments in Research at Kuopio University Hospital

Value in health, 2023-12, Vol.26 (12), p.S107-S108

2023

Volltextzugriff (PDF)

Modelling the Persistence of Disease-Modifying Drug Treatment (DMT) and its Independent Drivers in Finnish Multiple Sclerosis (MS) Patients: Parametric Survival Modelling

Value in health, 2014-11, Vol.17 (7), p.A400-A400

2014

Volltextzugriff (PDF)

Cost-Utility Analysis (Cua) of First-Line Actinic Keratosis (Ak) Treatments in Finland

Value in health, 2014-11, Vol.17 (7), p.A609-A609

2014

Volltextzugriff (PDF)

Episodes of Care and their Costs Based on ICPC-2 Classification: Three Month Follow-Up Study in Finland

Value in health, 2014-11, Vol.17 (7), p.A549-A549

2014

Volltextzugriff (PDF)

RWD63 Comparison of Certified Secure Processing Environments (SPE) – Novel Platforms for Collection, Augmentation, Structuring, Transfer, Management, Analysis, Sharing, Reporting, and Storage of Sensitive Data?

Value in health, 2022-12, Vol.25 (12), p.S460-S460

2022

Volltextzugriff (PDF)

FRI0184 Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A434-A434

2013

Volltextzugriff (PDF)

Cost-Effectiveness of First-Line Disease-Modifying Therapies (Dmts) For Relapsing-Remitting Ms (Rrms)

Value in health, 2015-11, Vol.18 (7), p.A756-A756

2015

Volltextzugriff (PDF)

Land use change patterns and livelihood dynamics on the slopes of Mt. Kilimanjaro, Tanzania

Agricultural systems, 2005-09, Vol.85 (3), p.306-323

Soini, Eija

2005

Volltextzugriff (PDF)

Cost-Effectiveness of Ustekinumab In The Treatment of Psoriasis In Finland

Value in health, 2015-11, Vol.18 (7), p.A670-A670

2015

Volltextzugriff (PDF)

REBELLIOUS FLOWERS IN THE GARDEN OF KATRI VALA

Yearbook of Finno-Ugric Studies, 2022-09, Vol.16 (3), p.451-461

Soini, Elena Grigoryevna

2022

Volltextzugriff (PDF)

Health Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine In Finnish Home Care Customers ≥50 Years With Underlying Chronic Medical Conditions

Value in health, 2015-11, Vol.18 (7), p.A579-A579

2015

Volltextzugriff (PDF)

POSA69 Coffee Drinking in Finland: Is It Value for Money? Cost-Effectiveness with User Interface Modelling

Value in health, 2022-01, Vol.25 (1), p.S46-S46

2022

Volltextzugriff (PDF)

EE239 Predictive Cost-Effectiveness Evaluation of Using a Machine Learning-Based Alzheimer’s Disease Risk Prediction Tool for Users of Social and Health Services Aged over 65 in Finland

Value in health, 2024-06, Vol.27 (6), p.S101-S101

2024

Volltextzugriff (PDF)

PDG11 Rebate, Discount, or Cost Saving - What Do These Mean for the Economic Risk Sharing Agreements? Case of Finnish Conditional Reimbursement System

Value in health, 2020-12, Vol.23, p.S522-S522

2020

Volltextzugriff (PDF)

PCP43 - HEALTH IMPACT MODELLING (HIM): CONCEPT, APPROACH AND REAL-WORLD DATA NEEDS FOR THE ESTIMATION OF POTENTIAL EFFECTIVENESS PROVIDED BY A PHARMA COMPANY PORTFOLIO

Value in health, 2018-10, Vol.21, p.S88-S88

2018

Volltextzugriff (PDF)

PHP7 - DIGITALIZATION AND CUSTOMER-RESPONSIVE SECONDARY CARE SERVICES POTENTIALLY FREE HEALTH CARE CAPACITY: PREDICTED MONETARY BENEFITS OF VIRTUAL HOSPITAL 2.0

Value in health, 2018-10, Vol.21, p.S151-S151

2018

Volltextzugriff (PDF)

EE361 From Biobank Sample to Breast Cancer Prevention—Cost-Effectiveness Analysis of Returning Genomic Data to Sample Donors

Value in health, 2023-12, Vol.26 (12), p.S120

2023

Volltextzugriff (PDF)

Triple therapy for incident pulmonary arterial hypertension in Finland between 2008 and 2020. A descriptive real-world FINPAH cohort study

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

HPR50 Life-YEARS Gained with Conditional Reimbursement Access to Innovative Oncological and Hematological Medicines in Finland

Value in health, 2022-07, Vol.25 (7), p.S475

2022

Volltextzugriff (PDF)

1 – 25 von 240

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(225)
Mit Volltextzugriff
(220)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Internal Medicine
(37)
Life Sciences & Biomedicine
(37)
Physical Sciences
(23)
Biological And Medical Sciences
(14)
Chemistry
(10)
Medical Sciences
(10)
Technology
(10)
Medicine, General & Internal
(8)
Physics
(8)
Chemistry, Analytical
(6)
Exact Sciences And Technology
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
Cost Analysis
(5)
Instruments & Instrumentation
(5)
Mortality
(5)
Optics
(5)
Public Health
(5)
Biochemistry & Molecular Biology
(4)
Chemistry, Multidisciplinary
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

RWD130 European Health Data Space (EHDS) Requires Secure Processing Environments (SPEs) – Comparison of SPESiOR to Other SPE-Type Environments from Finnish, Nordic, European, and Global Settings

Fluorescence-Based Cell Viability Screening Assays Using Water-Soluble Oxygen Probes

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland

PSY189 - TREATMENT GUIDELINE INCLUDING THE HEALTH ECONOMIC EVALUATIONS OF BIOLOGIC DRUGS USED FOR PSORIATIC ARTHRITIS: PICOSTEPS, SYSTEMATIC LITERATURE REVIEW, APPLICABILITY EVALUATION AND LEVEL OF EVIDENCE EVALUATION

CP3 - PATIENTS-INTERVENTION-COMPARATORS-OUTCOMES-SETTINGS-TIME-EFFECTS-SENSITIVITY (PICOSTEPS): REPRESENTING EVIDENCE-BASED HEALTH ECONOMIC EVALUATIONS (EBHEE) IN THE ORDER OF IMPORTANCE

Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

EE296 Should Hospitals Do Contract Research? Costs, Net Monetary Benefit, and Return on Public Sector Investments in Research at Kuopio University Hospital

Modelling the Persistence of Disease-Modifying Drug Treatment (DMT) and its Independent Drivers in Finnish Multiple Sclerosis (MS) Patients: Parametric Survival Modelling

Cost-Utility Analysis (Cua) of First-Line Actinic Keratosis (Ak) Treatments in Finland

Episodes of Care and their Costs Based on ICPC-2 Classification: Three Month Follow-Up Study in Finland

RWD63 Comparison of Certified Secure Processing Environments (SPE) – Novel Platforms for Collection, Augmentation, Structuring, Transfer, Management, Analysis, Sharing, Reporting, and Storage of Sensitive Data?

FRI0184 Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland

Cost-Effectiveness of First-Line Disease-Modifying Therapies (Dmts) For Relapsing-Remitting Ms (Rrms)

Land use change patterns and livelihood dynamics on the slopes of Mt. Kilimanjaro, Tanzania

Cost-Effectiveness of Ustekinumab In The Treatment of Psoriasis In Finland

REBELLIOUS FLOWERS IN THE GARDEN OF KATRI VALA

Health Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine In Finnish Home Care Customers ≥50 Years With Underlying Chronic Medical Conditions

POSA69 Coffee Drinking in Finland: Is It Value for Money? Cost-Effectiveness with User Interface Modelling

EE239 Predictive Cost-Effectiveness Evaluation of Using a Machine Learning-Based Alzheimer’s Disease Risk Prediction Tool for Users of Social and Health Services Aged over 65 in Finland

PDG11 Rebate, Discount, or Cost Saving - What Do These Mean for the Economic Risk Sharing Agreements? Case of Finnish Conditional Reimbursement System

PCP43 - HEALTH IMPACT MODELLING (HIM): CONCEPT, APPROACH AND REAL-WORLD DATA NEEDS FOR THE ESTIMATION OF POTENTIAL EFFECTIVENESS PROVIDED BY A PHARMA COMPANY PORTFOLIO

PHP7 - DIGITALIZATION AND CUSTOMER-RESPONSIVE SECONDARY CARE SERVICES POTENTIALLY FREE HEALTH CARE CAPACITY: PREDICTED MONETARY BENEFITS OF VIRTUAL HOSPITAL 2.0

EE361 From Biobank Sample to Breast Cancer Prevention—Cost-Effectiveness Analysis of Returning Genomic Data to Sample Donors

Triple therapy for incident pulmonary arterial hypertension in Finland between 2008 and 2020. A descriptive real-world FINPAH cohort study

HPR50 Life-YEARS Gained with Conditional Reimbursement Access to Innovative Oncological and Hematological Medicines in Finland

Aktive Filter

Suchergebnisse filtern